IDEAYA Biosciences Faces Collaboration Termination by GSK
I'm PortAI, I can summarize articles.
IDEAYA Biosciences announced that GSK will terminate their collaboration and license agreement effective March 9, 2026. GSK will transfer two clinical programs back to IDEAYA, which will explore strategic options for these programs. Despite the termination, IDEAYA expects its cash runway to last until 2030. Analysts rate IDYA stock as a Buy with a $64.00 price target, though Spark's AI Analyst views it as Neutral due to financial challenges and strategic risks.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments